Pheiron uses AI and real-world clinical outcomes to learn disease markers at population scale. Despite an explosion of biomedical data we are still in the dark about the most basic questions: Who will get sick, who will experience complications and how are these questions linked to human biology? Our disease markers integrate billions of data points of genetics, deep phenotypic information and clinical outcomes to answer these questions in silico and at scale. Our clients use our platform to guide drug discovery and development with actionable human-level evidence: for genomic due diligence of targets & programs and for de-risking phase II/III trials.

Subscribe to our blog to stay tuned for updates and latest insights on the drug development industry!